Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway
Ning Liu, Limei Yan, Fengping Shan, Xiaonai Wang, Na Qu, Mike K Handley, Mingxing Ma

Naltrexone (NTX) relieves inflammation in the collagen-induced- arthritis (CIA) rat models through regulating TLR4/NFκB signaling pathway
Xu N, Wang Y, Zhao S, Jiao T, Xue H, Shan F, Zhang N.

Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo
Liu N, Ma M, Qu N, Wang R, Chen H, Hu F, Gao S, Shan F.

Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway
Ma M, Wang X, Liu N, Shan F, Feng Y.

Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy
Li Z, You Y, Griffin N, Feng J, Shan F.

Functional modulation on macrophage by low dose naltrexone (LDN)
Yi Z, Guo S, Hu X, Wang X, Zhang X, Griffin N, Shan F.

Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs)
Meng J, Meng Y, Plotnikoff NP, Youkilis G, Griffin N, Shan F.

Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia
Parkitny L, Younger J.

Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis.
Ludwig MD, Turel AP, Zagon IS, McLaughlin PJ.

Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Hammer LA, Waldner H, Zagon IS, McLaughlin PJ.

The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain
Younger J, Parkitny L, McLain D.

Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn’s disease: a pilot study.
Smith JP, Field D, Bingaman SI, Evans R, Mauger DT.

Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels
Younger J, Noor N, McCue R, Mackey S.

Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
Donahue RN, McLaughlin PJ, Zagon IS.

The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN, McLaughlin PJ, Zagon IS.

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial.
Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS.

Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study.
Younger J, Mackey S.

Low-dose naltrexone therapy improves active Crohn’s disease.
Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS.

[Met⁵]-enkephalin preserves diffusion metrics in EAE mice.
Patel C, Meadowcroft MD, Zagon IS, McLaughlin PJ.

Methionine enkephalin inhibits influenza A virus infection through upregulating antiviral state in RAW264.7 cells.
Tian J, Qu N, Jiao X, Wang X, Geng J, Griffin N, Shan F.

Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) – opioid growth factor receptor (OGFr) axis.
Qu N, Wang X, Meng Y, Shan F.

Novel modulation on myeloid-derived suppressor cells (MDSCs) by methionine encephalin (MENK).
Geng J, Yuan Y, Jiao X, Wang R, Liu N, Chen H, Griffin N, Shan F.

Methionine enkephalin (MENK) regulates the immune pathogenesis of type 2 diabetes mellitus via the IL-33/ST2 pathway.
Zhang K, Yang J, Ao N, Jin S, Qi R, Shan F, Du J.

Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy
Wang R, Zhang Y, Shan F.

The novel mechanism of anticancer effect on gastric cancer through inducing G0/G1 cell cycle arrest and caspase-dependent apoptosis in vitro and in vivo by methionine enkephalin.
Wang X, Tian J, Jiao X, Geng J, Wang R, Liu N, Gao X, Griffin N, Gao Y, Shan F.

Intermittent blockade of OGFr and treatment of autoimmune disorders.
Zagon IS, McLaughlin PJ.

Rules to activate CD8⁺T cells through regulating subunits of opioid receptors by methionine enkephalin (MENK).
Jiao X, Wang X, Wang R, Geng J, Liu N, Chen H, Griffin N, Shan F.

Novel effect of methionine enkephalin against influenza A virus infection through inhibiting TLR7-MyD88-TRAF6-NF-κB p65 signaling pathway.
Tian J, Jiao X, Wang X, Geng J, Wang R, Liu N, Gao X, Griffin N, Shan F.

NFAT-1 hyper-activation by methionine enkephalin (MENK) significantly induces cell apoptosis of rats C6 glioma in vivo and in vitro.
Lu WC, Xie H, Tie XX, Wang R, Wu AH, Shan FP.

Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD, Zagon IS, McLaughlin PJ.

Methionine enkephalin (MENK) mounts antitumor effect via regulating dendritic cells (DCs).
Meng Y, Gao X, Chen W, Plotnikoff NP, Griffin N, Zhang G, Shan F.

Killing effect of methionine enkephalin on melanoma in vivo and in vitro.
Wang DM, Jiao X, Plotnikoff NP, Griffin N, Qi RQ, Gao XH, Shan FP.

(50+ more publications TBC)

Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
Brackett CM, Koiouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO, Abrams SI, Gudkov AV.

The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.
Yang H, Brackett C, Morales-Tirado V, Li Z, Zhang Q, Wilson M, Benjamin C, Harris W, Waller V, Gudkov AV, Burdelya L, Grossniklaus H.

The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates.
Krivokrysenko V, Toshkov I, Gleiberman A, Krasnov P, Shyshynova I, Bespalov I, Maitra R, Narizhneva N, Singh V, Whitnall M, Purmal A, Shakhov A, Gudkov AV, Feinstein E.

A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity.
Leigh ND, Bian G, Ding X, Liu H, Aygun-Sunar S, Burdelya LG, Gudkov AV, Cao X.

Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.
Kojouharov BM, Brackett CM, Veith JM, Johnson CP, Gitlin II, Toshkov IA, Gleiberman AS,Gudkov AV, Burdelya LG. 2014.

Developmental toxicity study of CBLB502 in Wistar rats.
Chow CP, Faqi AS.
Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.
Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova KI, Gleiberman AS, Aygun-Sunar S, Veith J, Johnson C, Haderski GJ, Stanhope-Baker P, Allamaneni S, Skitzki J, Zeng M, Martsen E, Medvedev A, Scheblyakov D, Artemicheva NM, Logunov DY, Gintsburg AL, Naroditsky BS, Makarov SS, Gudkov AV.

A TLR5 Agonist Enhances CD8+ T Cell-Mediated Graft-versus-Tumor Effect without Exacerbating Graft-versus-Host Disease.
Ding X, Bian G, Leigh ND, Qiu J, McCarthy PL, Liu H, Aygun-Sunar S, Burdelya LG, Gudkov AV, Cao X.

Identification of G-CSF and IL-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure.
Krivokrysenko V, Shakhov A, Singh V, Bone F, Kononov Y, Shyshynova I, Cheney A, Maitra R, Purmal A, Whitnall M, Gudkov AV, Feinstein E., 2012.

Structural Basis of TLR5-Flagellin Recognition and Signaling.
Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, Wilson IA.

Flagellin Takes Its Toll.
Mueller, K.

Toll-like Receptor 5 Agonist Protects Mice from Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer Radiotherapy.
Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, Bellnier D, Krivokrysenko VI, Feinstein E, Gudkov AV.

A TLR5 agonist inhibits acute renal ischemic failure.
Fukuzawa N, Petro M, Baldwin WM 3rd, Gudkov AV, Fairchild RL.

An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models.
Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, Kurnasov OV, Fort FL, Osterman AL, Didonato JA, Feinstein E, Gudkov AV., 2008.